MedCrypt

Deliberate C, and the honest grade despite prominent AI marketing. The core of Helm is a rules engine plus curated third-party exploitability data: component matching via an alias rules engine, lifecycle rules automating end-of-support tracking, and severity and exploitability drawn from EPSS, CISA KEV, ExploitDB, Metasploit, NVD and CWE Top 25. Those are external feeds and deterministic matching, not models. The genuine AI is narrower than the marketing implies: automated detection of which technology stacks a vulnerability affects, false positive suppression, and machine learning based risk mitigation recommendations. Real, but a layer on top. The actual moat is regulatory expertise and the medical-device-specific framing of general software supply chain tooling, which is why the company competes on being purpose-built for manufacturers rather than on model quality. Same principle applied to Reveleer, the credentialing lane and Censinet.

Automates assessment and scoring while leaving remediation decisions with the manufacturer's product security and regulatory teams. Auto-rescoring continuously monitors changes in vulnerability exploitability and fixability, with a reported reduction in assessment time of at least 90 percent, and bulk rescoring and bulk remediation import operate across a product portfolio. That bulk operation model is the notable autonomy feature and also the risk worth naming: applying a rescore or remediation decision across many device versions at once is efficient but concentrates the consequence of a wrong judgement. Graded B rather than A because no confidence threshold or human review gate is described for the AI-generated stack detection and recommendations.

The strongest transparency position in the cybersecurity lane, earned by naming its data sources precisely rather than describing proprietary intelligence. Helm's exploitability assessment is explicitly built on EPSS, CISA KEV, ExploitDB, Metasploit, NVD and CWE Top 25, all publicly identifiable sources a buyer can evaluate independently, and it supports CVSS 2, CVSS 3.x and EPSS scoring. The rules engine behaviour is documented publicly, including alias rules for component matching and lifecycle rules for end-of-support automation, and the company maintains public product documentation rather than gated materials. Naming your inputs allows a customer to reason about what the tool can and cannot know, which almost no vendor in this lane permits.

All performance evidence is vendor generated. The company publishes case studies stating Helm outperforms commercial and open source competitors on speed and accuracy, and claims at least 90 percent reduction in assessment time, but no independent benchmark, named customer result or disclosed methodology was located. Competitive case studies authored by the vendor comparing itself to unnamed competitors are the weakest evidence form in this index. That said, the regulatory analysis the company publishes, including work on FDA premarket deficiency trends, is substantive industry contribution even though it is not product evidence.

Structurally the cleanest PHI position of any vendor in this index, and it is worth stating why rather than treating it as absence of risk. MedCrypt's customers are device manufacturers, and the data it processes is software bills of materials, component inventories and vulnerability records. It does not touch patient data, hospital networks or clinical systems at all. There is no PHI surface to steward. Note one genuine security consideration the company itself raises, which is unusually candid: it warns that while the FDA recommends SBOMs be shared with customers for transparency, disclosure creates additional attack surface by revealing component details to threat actors, and states manufacturers must weigh that trade-off. Flagging the downside of a regulator's own recommendation is an admission against the compliance-tooling interest.

Not applicable in the usual sense. The company does not process protected health information, since its customers are device manufacturers and its data is software composition and vulnerability information. No BAA would ordinarily be required for this relationship.

No third party attestation such as SOC 2 Type II or ISO 27001 was retrieved at the time of review. As with every other vendor in this lane, a security company without a published security attestation is a notable gap, and it is arguably sharper here since customers are entrusting it with a complete map of the software composition and known weaknesses of their devices, which is a high-value target in itself.

Not itself an FDA regulated product, but graded A because regulatory alignment is the entire product proposition and it is executed with unusual precision. The offering maps directly to enforceable obligations: FDA Secure Product Development Framework implementation, SBOM generation and maintenance meeting NTIA minimum elements plus level of support and end-of-support dates per component, per-vulnerability safety and security risk assessments including CISA Known Exploited Vulnerabilities, postmarket monitoring for device lifetime, VEX and VDR reporting, the 12-document requirement for eSTAR submissions, and CISA incident reporting readiness. The company correctly frames the 2025 shift from guidance to enforceable statutory mandate under Section 524B and the Refuse to Accept policy, and publishes analysis of actual FDA premarket deficiency patterns. Few vendors in this index demonstrate this depth of regulatory literacy, and here it is the substance rather than a compliance claim.

No governance framework or model evaluation disclosure located. The relevant risk is false negatives rather than demographic bias: if AI-driven technology stack detection incorrectly determines a vulnerability does not affect a device, that vulnerability is suppressed from the manufacturer's view and may reach an FDA submission undisclosed, which the company's own analysis identifies as a leading cause of premarket deficiencies. No published false negative rate or validation of the suppression logic was located.

EHR integration is irrelevant to this buyer; the meaningful surface is the manufacturer's development toolchain. Helm offers an API and integration options to continuously ingest SBOM updates, supports manual creation and upload, and provides one-click generation of FDA-ready SBOM, VEX and VDR reports, with bulk remediation import across a device portfolio. Graded B rather than A because no named CI/CD, build system or product lifecycle management integrations were located, and continuous SBOM ingestion in a regulated development environment depends heavily on those connections.

Cloud platform by implication with public product documentation available, but no hosting architecture, deployment option or data residency disclosure was located at the time of review.

No pricing published and no pricing basis disclosed; the site routes to a demo request. The natural pricing unit would be per device or per product line under management, which matters because a manufacturer with a broad portfolio faces very different economics than one with a single device, and none of that is public.

Deep within a single well-defined buyer type rather than broad. Serves medical device manufacturers across R&D and engineering, quality and regulatory affairs teams handling 510(k), PMA and De Novo submissions, and product security and risk functions, spanning premarket submission through postmarket lifetime monitoring. The portfolio covers cryptography, SBOM and vulnerability management, and device monitoring. Graded B rather than A because coverage is confined to the manufacturer side with no health system or clinical deployment, and the index grades it on the same scale as vendors serving multiple settings.